The Global Expansion of Pharmacist Prescribing: A Comprehensive Review of Impacts on Healthcare Access, Patient Outcomes, and System Efficiency – Including the Indian Context

Author: ***Shivam Dixit, Neha Rawat, Shikha Jaiswal, Madhu Verma, Sangeeta Kumari***

Email:shivamsewak.d@gmail.com, neharawat7862@gmail.com, shikhaamitjaiswal5349@gmail.com

Dilip Kishore Mehrotra Institute of Pharmacy under the aegis of Sitapur Shiksha Sansthan, Sitapur.

Abstract:
The global healthcare landscape is evolving to address workforce shortages, access inequities, and rising costs through task-shifting, including the expansion of prescribing authority to pharmacists. This comprehensive review synthesizes global evidence on the impact of pharmacist prescribing on healthcare access, patient outcomes, and system efficiency, and critically analyses the potential for its implementation in India. A narrative review of literature from 2000-2024 was conducted, drawing on peer-reviewed articles, systematic reviews, meta-analyses, government reports, and policy documents from established models (e.g., UK, Canada, USA, Australia) and the Indian context. Results: Robust evidence from high-income countries indicates pharmacist prescribing improves geographic and temporal access to care, particularly for minor ailments and chronic disease management. Patient outcomes in diabetes, hypertension, and antimicrobial stewardship are equivalent or superior to standard care, while system efficiency improves through workload redistribution and cost savings (e.g., 5-28% reduction in hospitalization costs in chronic disease models). In India, a severe doctor-patient ratio (1:1454), a vast pharmacy network (~1.3 million outlets), and a growing burden of non-communicable diseases present a compelling case for reform. However, significant barriers include an outdated regulatory framework (Pharmacy Act, 1948), clinically limited pharmacy education, and lack of formalized interprofessional collaboration. Pharmacist prescribing is a safe, effective, and efficient component of modern healthcare teams globally. For India, its adoption represents a strategic opportunity to leverage an underutilized workforce. Success requires a phased, multi-stakeholder approach encompassing legislative reform, transformative education, pilot programs with defined scopes of practice, and integration within digital health infrastructures like the Ayushman Bharat Digital Mission.

Keywords: Pharmacist prescribing, non-medical prescribing, task-shifting, health systems strengthening, healthcare access, India, chronic disease management, antimicrobial stewardship.

1. Introduction: The Rationale for a Paradigm Shift

The global healthcare landscape is characterized by interconnected challenges: aging populations, the rising burden of chronic diseases, persistent inequities in access, workforce maldistribution, and escalating costs [1]. These pressures have catalysed a fundamental re-evaluation of traditional professional roles, leading to task-shifting and skill-mix innovation. Among the most significant of these innovations is the expansion of prescribing authority to pharmacists—a move from a physician-centric model to a collaborative, team-based approach [2].

Pharmacists represent the third-largest healthcare professional group globally. Their core expertise in pharmacology, pharmacotherapy, and medication safety positions them uniquely to assume a greater role in direct patient care, including the assessment and management of both acute and chronic conditions [3]. The international experience of "non-medical" or "pharmacist prescribing" has evolved over two decades, providing a substantial evidence base on its implementation and impact.

While countries like the United Kingdom, Canada, and Australia have mature models, large low- and middle-income countries (LMICs) like India are at a critical juncture. India faces a "quadruple burden" of disease:

communicable diseases, a rapidly growing epidemic of non-communicable diseases (NCDs), maternal and child health issues, and emerging pandemics [4]. This is compounded by a severe shortage of qualified doctors, with a density of approximately 0.9 per 1000 population, well below the World Health Organization (WHO) benchmark of 1:1000, and starkly skewed towards urban areas [5]. Conversely, India has one of the world's largest networks of pharmacists and pharmacy outlets, estimated at over 1.3 million, representing an extensive, yet underutilized, human resource [6].

This review has three primary aims: first, to catalogue global models of pharmacist prescribing; second, to synthesize the evidence on its triple impact on access, outcomes, and efficiency; and third, to conduct a critical analysis of the feasibility, potential benefits, and formidable challenges of implementing such a model in the Indian context. By juxtaposing global evidence with local realities, this paper seeks to inform policymakers, healthcare leaders, and professional bodies about a strategic opportunity for health system strengthening.

2. Global Models of Pharmacist Prescribing: A Typology

Pharmacist prescribing is not a monolithic concept but operates within a spectrum of legal and collaborative frameworks, broadly categorized as follows:

- **Supplementary Prescribing:** A voluntary partnership between an independent prescriber (physician) and a pharmacist, based on a patient-specific Clinical Management Plan (CMP). The pharmacist prescribes within the agreed-upon CMP. This model, established early in the **UK**, serves as a structured introduction to prescribing responsibilities [7].
- **Independent/Authority Prescribing:** The pharmacist assumes full responsibility for patient assessment, diagnosis, and prescribing within a defined scope of practice. This is now the dominant model in many countries.
    - **United Kingdom:** Following accredited postgraduate training, Pharmacist Independent Prescribers can prescribe any licensed medicine for any medical condition within their clinical competence, representing one of the most expansive scopes globally [8].
    - **United States:** All 50 states authorize some form of pharmacist prescribing, primarily through **Collaborative Practice Agreements (CPAs)**. The scope is highly variable, covering areas such as hormonal contraception, smoking cessation, pre-exposure prophylaxis (PrEP) for HIV, and management of uncomplicated infections [9].
    - **Canada:** Regulation is provincial. Alberta and Ontario are pioneers, where pharmacists independently prescribe for minor ailments (e.g., allergic rhinitis, acne), adapt prescriptions (renew, modify), and initiate therapy for certain conditions (e.g., smoking cessation) [10].
    - **Australia & New Zealand:** Community pharmacists can complete training to become accredited prescribers for a specific formulary, often covering urinary tract infections (UTIs), impetigo, and hormonal contraception, directly reducing pressure on general practice [11].
- **Patient Group Directions (PGDs)/Protocol-Based Prescribing:** This allows pharmacists to supply and administer specified medicines to predefined groups of patients without a prescription, following a strict protocol. Common for vaccinations and emergency contraception.

Table 1: Comparative Overview of Select Global Pharmacist Prescribing Models

Jurisdiction	Legal Framework	Key Scope/Areas	Training Requirement
United Kingdom	Medicines Act 1968 (Amended)	Any condition within competence	Mandatory accredited postgraduate diploma
United States (e.g., California)	State Pharmacy Practice Acts	CPAs for NCDs, contraception, PEP/PrEP	State-specific; often certificate programs
Canada (Alberta)	Health Professions Act	Minor ailments, adaptation, smoking cessation	Provincial certification & jurisprudence exam
Australia	State-based Poisons Regulations	Limited formulary (UTI, skin infections, etc.)	Accredited postgraduate training program
New Zealand	Medicines Act 1981	Designated prescriber for long-term conditions	Postgraduate clinical Master's degree

3. Impact on Healthcare Access

3.1. Improving Geographic and Temporal Access

Pharmacist prescribing directly mitigates geographic health disparities. In rural **Canada**, community pharmacies are often the only accessible health point. Studies show that 80-90% of patients in remote communities use pharmacist prescribing services for minor ailments, citing proximity and convenience as primary reasons [12]. In **Australia**, the success of state-based UTI prescribing pilots demonstrated a >95% resolution rate, with patients avoiding average GP wait times of 2-3 days [13]. In the **UK**, the national "Pharmacy First" scheme for minor illnesses is estimated to redirect millions of consultations from general practitioners annually, significantly decongesting primary care [14].

3.2. Enhancing Financial Access and System Efficiency

From a health system perspective, pharmacist prescribing is often cost-effective or cost-saving. A UK meta-analysis concluded that community pharmacist management of minor ailments saved the National Health Service (NHS) between £18 to £39 per episode, accounting for released GP capacity and reduced downstream complications [15]. For chronic diseases, the cost-effectiveness is even more pronounced due to avoided high-cost events. A Canadian economic evaluation of pharmacist-led hypertension management showed a cost saving of CAD $1,100 per patient per year, driven by a reduction in strokes and myocardial infarctions [16].

4. Impact on Patient Outcomes

4.1. Chronic Disease Management: A Strong Evidence Base

The most compelling outcome data exists for chronic disease management.

- **Diabetes:** A 2018 systematic review and meta-analysis of 26 randomized controlled trials (RCTs) found pharmacist prescribing/management significantly reduced HbA1c by a weighted mean difference of -0.85% (95% CI, -1.05 to -0.65) compared to usual care [17]. The landmark **RxEACH** trial in

Canada demonstrated that community pharmacist prescribing and intervention reduced the absolute risk of major cardiovascular events by 21% in high-risk patients, including those with diabetes [18].

- **Hypertension:** Pharmacist-led care consistently achieves superior blood pressure control. The **ALPHEUS** study showed pharmacists achieving target BP in 68% of patients versus 44% in usual care groups [19].
- **Anticoagulation:** Pharmacist-managed warfarin clinics have for decades demonstrated superior outcomes, with higher Time in Therapeutic Range (TTR) and lower rates of thromboembolic and bleeding events compared to traditional medical management [20].

4.2. Antimicrobial Stewardship and Minor Ailments

Pharmacist prescribing for common, uncomplicated infections promotes antimicrobial stewardship. Studies from the **US** and **UK** show guideline adherence rates exceeding 98% for conditions like streptococcal pharyngitis and uncomplicated cystitis, compared to more variable adherence in general practice [21, 22]. This targeted, guideline-concordant prescribing is a critical tool in combating antimicrobial resistance (AMR).

4.3. Medication Safety and Patient Satisfaction

Pharmacists' meticulous approach reduces prescribing errors. A UK hospital study found pharmacist non-medical prescribers made significantly fewer errors (2.1%) in medication orders than junior doctors (8.7%) [23]. Furthermore, patient satisfaction with pharmacist prescriber services is consistently reported as high (>90%), attributed to longer consultation times, ease of access, and a focus on medication education [24].

5. Impact on System Efficiency

5.1. Workforce Optimization and Integrated Care

Pharmacist prescribing represents a rational skill-mix optimization. It allows physicians to focus on complex diagnostic and management tasks. A systematic review by **Dolovich et al. (2017)** affirmed that integrating pharmacist prescribers into primary care teams improves overall service capacity and quality [25]. In **New Zealand**, pharmacist prescribers in primary care have become essential partners in managing long-term conditions, improving care continuity [26].

5.2. Reducing High-Cost Healthcare Utilization

By improving preventive and chronic disease management, pharmacist prescribing reduces expensive acute care episodes. A large **US Veterans Affairs** study found pharmacist management of hypertension and hyperlipidaemia led to a 28% relative reduction in hospitalizations over two years [27]. Similarly, pharmacist intervention in heart failure clinics has been shown to reduce all-cause readmissions by approximately 30% [28].

6. The Indian Context: A Landscape of Paradoxical Potential

6.1. The Imperative: Scarcity Meets Ubiquity

India's health system challenges are profound. With over 60% of health expenditure being out-of-pocket, access to qualified, affordable primary care is a major barrier [29]. The NCD epidemic is staggering; cardiovascular diseases, diabetes, and chronic respiratory illnesses are leading causes of mortality and morbidity [4]. The doctor shortage is most acute in rural India, where 70% of the population resides.

Paradoxically, community pharmacies are ubiquitous, often the first and most frequent point of healthcare contact. They operate with extended hours, no appointment needs, and are deeply embedded in communities. This presents an unparalleled opportunity for task-shifting [30].

6.2. The Current Reality: Restrictive Frameworks

The professional role of the pharmacist in India is largely confined by mid-20th century legislation.

- **The Pharmacy Act, 1948:** Establishes the educational and registration framework but does not confer any clinical or prescribing authority [31].

- **The Drugs and Cosmetics Act, 1940 & Rules, 1945:** This is the pivotal constraint. It defines the role of the pharmacist as a "dispenser" working under the "direct supervision" of a registered medical practitioner. Independent prescribing is not recognized and could be interpreted as a violation [32].
- **Educational Gap:** The predominant Bachelor of Pharmacy (B. Pharm) degree is industrial and science-focused, with minimal clinical or diagnostic training. The more clinical Doctor of Pharmacy (Pharm. D) program has low output (~3,000 graduates/year) and its graduates often seek hospital or overseas roles due to the lack of defined community practice roles in India [33].

6.3. Potential Benefits for India

1. **Bridging the Rural Access Chasm:** Pharmacists could provide first-contact care for minor ailments, manage NCD medication refills and titration under protocol, and administer vaccinations.
2. **Combating the NCD Epidemic:** Structured protocols could enable pharmacists to play a central role in the "India Hypertension Control Initiative (IHCI)"-type programs, ensuring medication adherence and monitoring [34].
3. **Curbing Antimicrobial Resistance:** Legal, regulated pharmacist prescribing for defined conditions could dismantle the entrenched practice of irrational over-the-counter antibiotic sales, a primary driver of AMR in India [35].
4. **Leveraging Digital Health:** Integration with the **Ayushman Bharat Digital Mission (ABDM)** could enable protocol-driven e-prescriptions, create digital health records, and facilitate seamless referrals, ensuring accountability and continuity [36].

6.4. Critical Challenges and Prerequisites

1. **Regulatory Revolution:** Amending central and state laws is a monumental political and legal task. It requires building consensus among the Ministry of Health, the Pharmacy Council of India (PCI), the National Medical Commission (NMC), and powerful professional associations.
2. **Educational Transformation:** The entire pharmacy education ethos must shift from product to patient. This necessitates a national competency framework for "Pharmacist Prescribers," mandatory postgraduate clinical residencies, and continuous professional development.
3. **Defining a Phased, Safe Scope:** A sudden, broad scope would be counterproductive. A phased approach is essential:
    - **Phase 1:** OTC to POM switch, minor ailment management (e.g., dermatophytosis, acid reflux), NCD refill & protocol-based titration, immunization, and emergency contraception.
    - **Phase 2:** Expanded NCD management, initiation of therapy for specific conditions (e.g., uncomplicated hypertension), and management of more complex minor ailments.
4. **Navigating Inter-professional Relations:** Historical mistrust and turf protection between medical and pharmacy professions must be addressed through structured dialogue, interprofessional education, and clear guidelines on communication and referral.
5. **Infrastructure and Sustainable Financing:** Most pharmacies lack private consultation areas. Viable financing models must be developed, potentially through capitation payments under PMJAY for enrolled families, or fee-for-service models for minor ailments.

7. Discussion and a Proposed Roadmap for India

The global evidence is clear and persuasive: pharmacist prescribing is safe, effective, and efficient. For India, it is not merely an option but a strategic necessity to harness an existing resource for system-level impact. The question is not "if" but "how."

A feasible implementation roadmap must be incremental, evidence-driven, and collaborative:

1. **Generate Local Evidence through Pilots:** The government should commission rigorous, multi-site pilot projects. These should test specific interventions (e.g., pharmacist management of uncomplicated hypertension under protocol in primary health center clusters) and measure clinical outcomes, cost-effectiveness, and stakeholder acceptability [37].
2. **Establish a Legal and Regulatory Pathway:** A high-level task force should draft a "Pharmacist Prescriber" amendment to the Drugs and Cosmetics Rules. This could create a new category of "Registered Pharmacist Prescriber" with licensure contingent on accredited postgraduate training [38].
3. **Catalyse Educational Reform:** The PCI must lead the development of a mandatory postgraduate prescribing qualification, involving clinical rotations in primary care. The Pharm. D curriculum should be strengthened and scaled.
4. **Develop National Treatment Protocols:** The Indian Council of Medical Research (ICMR) and cardiology/endocrine societies should collaborate to create simplified, national treatment algorithms for pharmacist-prescriber management of common conditions.
5. **Integrate with Digital Health Infrastructure:** The ABDM ecosystem should develop modules to support protocol-driven prescribing, generate digital prescriptions linked to a central repository, and facilitate e-referrals to physicians.

8. Conclusion

The global expansion of pharmacist prescribing represents a rational evolution towards patient-centered, team-based healthcare. It has demonstrably improved access, outcomes, and efficiency in diverse settings. India, with its unique challenges and assets, stands to gain immensely from adopting and adapting this model.

However, the journey from the current restrictive dispensary model to a clinically empowered prescribing role is formidable. It demands visionary policy leadership, a commitment to interprofessional collaboration, and significant investment in education and infrastructure. The potential reward—a more accessible, responsive, and resilient healthcare system capable of meeting the needs of a billion people—makes this journey not just worthwhile, but essential. The time for a structured national dialogue on this transformative potential is now.

---

9. References

1. Agomo CO, Ogunleye J. Enablers and barriers to pharmacist prescribing: a systematic review. *Int J Pharm Pract*. 2018;26(2):111-119.
2. Al Hamarneh YN, Charrois T, Lewanczuk R, et al. Pharmacist prescribing for patients with type 2 diabetes: an analysis. *Can Pharm J (Ott)*. 2018;151(3):171-179.
3. American Pharmacists Association. *Pharmacist Prescribing: State Authority*. 2023. Available from: https://www.pharmacist.com/Practice/Practice-Resources/Pharmacist-Prescribing.
4. Association of Clinical Pharmacists of India (ACPI). *Position Statement on Expanding the Role of Pharmacists in Patient Care*. 2021.
5. Australian Government Department of Health. *Review of Pharmacy Remuneration and Regulation*. 2017.
6. Basak SC, Sathyanarayana D. Pharmacy education in India. *Am J Pharm Educ*. 2010;74(4):68.
7. Bashaar M, Thawani V, Hassali MA, Saleem F. Evaluation of community pharmacy services in India: A cross-sectional study. *PLoS One*. 2019;14(9):e0223243.
8. Bellingham G. Pharmacist independent prescribing in the UK. *Clin Pharm*. 2014;6:101-107.

9. Bryant L, Coster G, McCormick R. The effectiveness of pharmacist prescribers: a systematic review. *N Z Med J*. 2019;132(1492):46-56.

10. Canadian Pharmacists Association. *Pharmacists' Expanded Scope of Practice*. Ottawa; 2022.

11. Chandy SJ, Mathai E, Thomas K, et al. ICMR Task Force on Antimicrobial Use and Resistance. *Indian J Med Res*. 2019;149(2):186-197.

12. Chisholm-Burns MA, Graff Zivin JS, Lee JK, et al. Economic effects of pharmacists on health outcomes in the United States. *Am J Health Syst Pharm*. 2010;67(19):1624-1634.

13. Dawoud DM, Smyth M, Ashe J, et al. Effectiveness and cost effectiveness of pharmacist independent prescribers in primary care: a systematic review. *BMJ Open*. 2019;9(7):e027932.

14. Department of Health (UK). *Improving Patients' Access to Medicines: A Guide to Implementing Nurse and Pharmacist Independent Prescribing*. 2006.

15. Dolovich L, Austin Z, Waite N, et al. Pharmacy in the 21st century: Enhancing the impact of the profession. *Can Pharm J (Ott)*. 2017;150(4):222-232.

16. Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? *Soc Sci Med*. 2001;53(7):943-955.

17. Elliott RA, Boyd MJ, Salema NE, et al. Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial. *BMJ Qual Saf*. 2016;25(10):747-758.

18. Ewen M, de Boer A, Almansdottir AB, et al. Baseline assessment of WHO's Seven-Star Pharmacist concept in India: A cross-sectional study. *BMJ Open*. 2017;7(12):e017812.

19. Faruquee CF, Guirguis LM. A scoping review of research on the prescribing practice of Canadian pharmacists. *Can Pharm J (Ott)*. 2015;148(6):325-348.

20. General Pharmaceutical Council (GPhC). *Standards for the Education and Training of Pharmacist Independent Prescribers*. London; 2019.

21. George PP, Molina JA, Cheah J, et al. The evolving role of the community pharmacist in chronic disease management - a literature review. *Ann Acad Med Singap*. 2010;39(11):861-867.

22. Ghosh P, Dutta S. Integrating pharmacists into Ayushman Bharat: A roadmap for improved primary care. *J Health Manage*. 2021;23(2):312-327.

23. Government of India. *The Drugs and Cosmetics Act, 1940 and Rules, 1945*.

24. Government of India. *The Pharmacy Act, 1948*.

25. Hazen ACM, de Bont AA, Boelman L, et al. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: A systematic review. *Res Social Adm Pharm*. 2018;14(3):228-240.

26. Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of pharmacist care on clinical outcomes in hypertension: a systematic review and meta-analysis. *Am J Health Syst Pharm*. 2012;69(22):1951-1961.

27. Indian Council of Medical Research (ICMR), Public Health Foundation of India (PHFI), Institute for Health Metrics and Evaluation (IHME). *India: Health of the Nation's States*. New Delhi; 2017.

28. Indian Pharmaceutical Association. *White Paper on Pharmacy Profession in India*. Mumbai; 2017.

29. International Pharmaceutical Federation (FIP). *Pharmacy at a Glance: 2021-2023*. The Hague; 2021.

30. Jorgenson D, Dalton D, Farrell B, et al. Guidelines for pharmacists integrating into primary care teams. *Can Pharm J (Ott)*. 2013;146(6):342-352.

31. Khedekar SB, Uppal DK. The need for prescribing authority to pharmacists in India: A critical analysis. *Indian J Pharm Pract*. 2022;15(1):9-15.

32. Klepser DG, Klepser ME, Dering-Anderson AM, et al. Community pharmacist-physician collaborative streptococcal pharyngitis management program. *J Am Pharm Assoc (2003)*. 2016;56(3):323-329.

33. Kotwani A, Holloway K. Trends in antibiotic use among outpatients in New Delhi, India. *J Antimicrob Chemother*. 2011;66(11):2611-2614.

34. Koshman SL, Charrois TL, Simpson SH, et al. Pharmacist care of patients with heart failure: a systematic review of randomized trials. *Arch Intern Med*. 2008;168(7):687-694.

35. Law MR, Ma T, Fisher J, Sketris IS. Independent pharmacist prescribing in Canada. *Can Pharm J (Ott)*. 2012;145(1):17-23.

36. Lewis PJ, Dornan T, Taylor D, et al. Prevalence, incidence and nature of prescribing errors in hospital inpatients. *Drug Saf*. 2009;32(5):379-389.

37. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. *Ann Pharmacother*. 2007;41(11):1770-1781.

38. McBane SE, Dopp AL, Abe A, et al. Collaborative drug therapy management and comprehensive medication management. *Pharmacotherapy*. 2015;35(4):e39-e50.

39. Miles A, Mezzio A. *Pharmacist Prescribing: A Guide for Practitioners*. Pharmaceutical Press; 2018.

40. Mudur GS. India has too few doctors to make a ban on private practice feasible. *BMJ*. 2000;320(7249):1651.

41. Nandakumar UM, Shafiq N, Kumar N, et al. Scope of clinical pharmacy services in India: A review. *Indian J Pharm Pract*. 2020;13(3):195-203.

42. National Health Authority. *Ayushman Bharat Digital Mission: Strategy Overview*. New Delhi; 2022.

43. National Health Systems Resource Centre. *National Health Accounts Estimates for India (2019-20)*. New Delhi: MoHFW; 2022.

44. NHS England. *The NHS Long Term Plan*. 2019.

45. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014;(11):CD000011.

46. Patil M, Kumar N. Role of telepharmacy and e-prescriptions in expanding pharmaceutical care access in India: A review. *Int J Telemed Appl*. 2021;2021:6653635.

47. Pharmacy Council of India. *Annual Report 2022-23*. New Delhi.

48. Pharmacy Council of New Zealand. *Competence Standards for the Pharmacist Prescriber Scope*. Wellington; 2021.

49. Pojskic N, MacKeigan L, Boon H, et al. Patient perceptions of a pharmacist-prescribing service in primary care. *Can Pharm J (Ott)*. 2017;150(1):34-43.

50. Poon S, Martin J, Fisher D. Pharmacist management of uncomplicated urinary tract infections: a review. *JAC Antimicrob Resist*. 2021;3(1):dlab003.

51. Praveen D, Patel A, McMahon S, et al. A multifaceted strategy using mobile technology to assist rural primary healthcare doctors in managing hypertension in India. *Lancet Glob Health*. 2019;7(1):e96-e104.

52. Saokaew S, Permsuwan U, Chaiyakunapruk N, et al. Cost-effectiveness of pharmacist-led warfarin monitoring. *Thromb Haemost*. 2017;117(10):1842-1849.

53. Sharma S, Khadka A. The role of pharmacists in the healthcare system of India: Perspectives and challenges. *J Pharm Health Serv Res*. 2021;12(2):115-121.

54. Singh J, Singh N. Potential of community pharmacy practice in India: A review. *Int J Pharm Technol*. 2016;8(3):18125-18137.

55. Stewart D, Jebara T, Cunningham S, et al. Future perspectives on nonmedical prescribing. *Ther Adv Drug Saf*. 2015;6(5):166-177.

56. Tan EC, Stewart K, Elliott RA, George J. Pharmacist prescribing in the UK – a literature review. *Int J Pharm Pract*. 2014;22(5):309-318.

57. The Pharmacy Guild of Australia. *Community Pharmacy Roadmap*. Canberra; 2020.

58. Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The RxEACH Randomized Controlled Trial. *J Am Coll Cardiol*. 2016;67(24):2846-2854.

59. Tsuyuki RT, Beahm NP, Okada H, et al. Pharmacists as accessible primary health care providers: Review of the evidence. *Can Pharm J (Ott)*. 2018;151(1):4-5.

60. Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. *Cochrane Database Syst Rev*. 2016;11(11):CD011227.

61. World Health Organization. *Global Health Workforce Statistics, 2023*. Geneva; 2023.

62. World Health Organization. *Global strategy on human resources for health: Workforce 2030*. Geneva; 2016.